Correlation between Levels of Serum Lipoprotein-Associated Phospholipase A2 and Soluble Suppression of Tumorigenicity 2 and Condition of Acute Heart Failure Patients and Their Predictive Value for Prognosis

Table 1

General information.

Group	Mild (n = 55)	Severe (n = 50)	X^2/t
Gender (male/female)	30/25	28/22	0.022	0.881
Age (years)	74.68 ± 2.65	74.99 ± 2.60	0.604	0.547
Mean body weight (kg)	60.69 ± 2.45	61.01 ± 2.85	0.618	0.538
BMI (kg/m^2)	23.45 ± 1.20	23.57 ± 1.24	0.504	0.616
Height (cm)	173.65 ± 12.40	173.98 ± 11.68	0.140	0.889
Medical history
Valvular heart disease	10	12	0.535	0.464
Hypertension	18	19	0.319	0.572
Diabetes	15	12	0.147	0.702
CHD	15	16	0.281	0.596
Congestive HF	10	8	0.088	0.767
LVEF (%)	50.55 ± 15.68	43.58 ± 15.40	2.294	0.024
High-sensitivity CRP (mg/L)	13.54 ± 4.68	28.65 ± 8.98	10.953	<0.001
Hemoglobin (g/L)	130.65 ± 8.99	122.98 ± 9.21	4.316	<0.001
Creatinine (μmol/L)	95.62 ± 10.11	131.68 ± 12.35	16.431	<0.001
Uric acid (μmol/L)	430.98 ± 56.32	489.65 ± 62.98	5.039	<0.001